InMode Ltd. (NASDAQ:INMD) Receives Consensus Rating of "Hold" from Analysts

Key Points

• InMode (NASDAQ:INMD) has a consensus analyst rating of Hold from nine firms (1 sell, 7 hold, 1 buy) and an average 12‑month price target of $16.80.
• The company beat EPS estimates, reporting $0.46 vs. $0.42 consensus, while revenue was $103.85M—slightly below the $104.64M estimate—but up 6.1% year‑over‑year.
• Institutional ownership stands at 68.04%, with notable position increases from Doma Perpetual, Millennium Management and Goldman Sachs in recent quarters.

Shares of InMode Ltd. (NASDAQ:INMD - Get Free Report) have been assigned an average recommendation of "Hold" from the nine research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $16.80.

Several research firms have commented on INMD. Canaccord Genuity Group set a $15.00 price target on InMode and gave the company a "hold" rating in a report on Wednesday, December 17th. Weiss Ratings reissued a "sell (d+)" rating on shares of InMode in a report on Thursday, January 22nd. Robert W. Baird set a $17.00 price target on InMode in a research report on Wednesday, February 11th. Finally, BTIG Research restated a "neutral" rating on shares of InMode in a research report on Monday, January 26th.

InMode Stock Performance

NASDAQ INMD opened at $13.53 on Monday. InMode has a twelve month low of $12.72 and a twelve month high of $16.74. The stock has a market capitalization of $857.26 million, a PE ratio of 9.40 and a beta of 2.12. The stock has a 50-day simple moving average of $14.00 and a 200 day simple moving average of $14.45.

InMode (NASDAQ:INMD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The healthcare company reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.04. InMode had a return on equity of 14.52% and a net margin of 25.33%.The business had revenue of $103.85 million during the quarter, compared to analysts' expectations of $104.64 million. During the same quarter in the previous year, the firm earned $0.42 EPS. The firm's revenue was up 6.1% compared to the same quarter last year. As a group, equities research analysts forecast that InMode will post 1.75 EPS for the current fiscal year.

Institutional Investors Weigh In On InMode

A number of large investors have recently bought and sold shares of the business. Doma Perpetual Capital Management LLC grew its position in InMode by 26.8% during the 3rd quarter. Doma Perpetual Capital Management LLC now owns 2,838,431 shares of the healthcare company's stock worth $42,293,000 after acquiring an additional 599,108 shares during the last quarter. Millennium Management LLC boosted its position in InMode by 111.4% in the 4th quarter. Millennium Management LLC now owns 1,778,681 shares of the healthcare company's stock valued at $26,129,000 after buying an additional 937,376 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in InMode by 48.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,422,635 shares of the healthcare company's stock valued at $20,899,000 after buying an additional 466,891 shares during the last quarter. Cooper Creek Partners Management LLC bought a new position in InMode in the 3rd quarter valued at $14,980,000. Finally, Ancient Art L.P. bought a new position in InMode in the 3rd quarter valued at $14,254,000. 68.04% of the stock is currently owned by institutional investors.

About InMode

InMode Ltd. NASDAQ: INMD is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode's product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.